Last reviewed · How we verify
Cisplatin/Platinol
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and triggering cancer cell death.
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and triggering cancer cell death. Used for Metastatic testicular cancer, Metastatic ovarian cancer, Advanced bladder cancer.
At a glance
| Generic name | Cisplatin/Platinol |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Platinum-based alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which distort the DNA helix and block DNA synthesis and transcription. This leads to apoptosis in rapidly dividing cancer cells. It is a non-cell-cycle-specific alkylating agent that has been a cornerstone of cancer chemotherapy for decades.
Approved indications
- Metastatic testicular cancer
- Metastatic ovarian cancer
- Advanced bladder cancer
- Head and neck cancer
- Non-small cell lung cancer
- Small cell lung cancer
Common side effects
- Nephrotoxicity
- Ototoxicity
- Nausea and vomiting
- Myelosuppression (thrombocytopenia)
- Myelosuppression (leukopenia)
- Peripheral neuropathy
- Anemia
- Electrolyte abnormalities (hypomagnesemia)
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |